# A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

> **NCT06095986** · PHASE2 · WITHDRAWN · sponsor: **Galmed Pharmaceuticals Ltd**

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Aramchol meglumine

## Key facts

- **NCT ID:** NCT06095986
- **Lead sponsor:** Galmed Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06
- **Primary completion:** 2026-09
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Operational and clinical reasons
- **Last updated:** 2025-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06095986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06095986, "A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06095986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*